Intestinal flora and portal hypertension
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. The patients with liver cirrhosis (according to clinical, laboratory, imaging, or liver biopsy) have been measured for the first time; 2. The patients with HVPG > 12mmhg and planned to take non selective ß receptor blocker; 3. Patients who had no history of gastrointestinal bleeding or esophageal varices bleeding before, and 5 days after acute bleeding; 4. Patients with moderate or severe esophageal and gastric varices confirmed by gastroscope; 5. Patients aged 18-75; 6. Patients willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients taking nsbbs or other drugs to treat portal hypertension in the past 6 weeks; 2. Patients with persistent bacterial infection requiring antibiotic treatment; 3. Patients who used antibiotics or immunomodulators in the past 2 weeks; 4. Patients taking microecological preparations in the past 6 weeks; 5. Patients with alcohol intake or illicit drug abuse in the past 6 weeks; 6. Patients with contraindications to use nsbbs, such as bronchial asthma, cardiogenic shock, heart block (II - III degree atrioventricular block), severe or acute heart failure and sinus bradycardia; 7. Patients taking drugs that affect the metabolism and absorption of nsbbs at the same time; 8. Patients with liver cancer or extrahepatic tumor; 9. Patients with severe heart, lung, liver and kidney dysfunction, or severe bleeding disease or local / systemic infection, hypothyroidism, Raynaud's syndrome, peripheral vascular disease, etc; 10. Patients with severe portal vein thrombosis; 11. Women who plan to be pregnant or who have been pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intestinal flora;HVPG response of NSBBs; | — |
Countries
China
Contacts
Department of Gastroenterology, Gulou Hospital affiliated to Nanjing University School of Medicine